{"id":7460,"date":"2020-02-04T15:39:36","date_gmt":"2020-02-04T10:09:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7460"},"modified":"2022-08-16T10:12:38","modified_gmt":"2022-08-16T04:42:38","slug":"recent-pharma-happenings-for-aimmune-insmed-united-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics","title":{"rendered":"First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed&#8217;s shares Soares"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\" id=\"h-the-us-fda-has-given-its-recommendation-to-the-aimmune-therapeutics-drug-palforzia-the-first-ever-treatment-for-peanut-allergy\"><strong>The US FDA has given its recommendation to the Aimmune Therapeutics\u2019 drug, Palforzia, the first-ever treatment for Peanut Allergy. <\/strong><\/h3>\n\n\n\n<p>Palforzia is an oral immunotherapy, set to address the unmet needs in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-pipeline-insight\">Peanut market<\/a>, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may occur due to accidental exposure to peanut.&nbsp;<\/p>\n\n\n\n<p>Peanut allergy is one of the most common <a href=\"https:\/\/www.delveinsight.com\/blog\/global-allergic-disease-market\">allergies <\/a>among infants and young children, with a total <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\">Peanut allergy<\/a> prevalence 8,640,527 in 2017, in the 7MM, estimates DelveInsight.\u00a0<\/p>\n\n\n\n<p>The therapy, Palforzia, is designed to increase the tolerance of peanut, desensitizing the patients over time. With the approval, Aimmune Therapeutics will stay six months ahead of its competitor DBV technologies, which is manufacturing a patch-based therapy for treating peanut allergy. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-united-therapeutics-has-announced-the-failure-of-its-unituxin-dinutuximab-with-irinotecan-combo-to-meet-primary-endpoint\"><strong>United Therapeutics has announced the failure of its Unituxin (dinutuximab) with irinotecan combo to meet primary endpoint. <\/strong><\/h3>\n\n\n\n<p>The trial Phase II\/III \u2013 DISTINCT, was evaluating the combination of Unituxin (dinutuximab) with irinotecan compared to irinotecan or topotecan alone in relapsed or refractory <a href=\"https:\/\/www.delveinsight.com\/report-store\/small-cell-lung-cancer-market\">small cell lung cancer<\/a> (SCLC).&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/small-cell-lung-cancer-epidemiology-forecast\">Small cell lung cancer<\/a> accounts for 15% of total cancer with a higher preponderance in males as compared to females in the 7MM.&nbsp;<\/p>\n\n\n\n<p>Already approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), Unituxin, is a GD2-binding monoclonal antibody, for the treatment of children with high-risk neuroblastoma. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-new-jersey-based-insmed-incorporated-announced-positive-phase-ii-results-for-ins1007-for-adults-with-non-cystic-fibrosis-bronchiectasis-ncfbe\"><strong>New Jersey-based Insmed Incorporated announced positive Phase II results for INS1007 for adults with non-cystic fibrosis bronchiectasis (NCFBE). <\/strong><\/h3>\n\n\n\n<p>The company\u2019s stock is up more than 36% in early trading today.<\/p>\n\n\n\n<p>The mid-Stage WILLOW study met its primary end-point, presenting a potential picture of INS1007, a novel, oral, selective, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), inhibiting the production of neutrophils, which accumulate in the airways causing lung inflammation.&nbsp;<\/p>\n\n\n\n<p>At present, there are no currently approved treatments or therapies, giving INS1007 an edge in the market targeting <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market\">NCFBE<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US FDA has given its recommendation to the Aimmune Therapeutics\u2019 drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may occur due to accidental exposure to peanut.&nbsp; Peanut allergy [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7461,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17434,32],"tags":[17937,349,18004,6428,18002,18005,639,5789,1701,18003],"industry":[17225],"therapeutic_areas":[17227,17228],"class_list":["post-7460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-facts-and-figures","category-notizia","tag-aimmune-therapeutics","tag-latest-pharma-news","tag-non-cystic-fibrosis-bronchiectasis","tag-palforzia","tag-peanut-allergy-treatment","tag-peanut-market","tag-pharma-news","tag-recent-pharma-news","tag-small-cell-lung-cancer","tag-united-therapeutics","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint<\/title>\n<meta name=\"description\" content=\"Peanut allergy is one of the most common allergies among infants and young children, with a total Peanut allergy prevalence 8,640,527 in 2017, in the 7MM.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint\" \/>\n<meta property=\"og:description\" content=\"Peanut allergy is one of the most common allergies among infants and young children, with a total Peanut allergy prevalence 8,640,527 in 2017, in the 7MM.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-04T10:09:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-16T04:42:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/04153626\/slide2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint","description":"Peanut allergy is one of the most common allergies among infants and young children, with a total Peanut allergy prevalence 8,640,527 in 2017, in the 7MM.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics","og_locale":"en_US","og_type":"article","og_title":"First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint","og_description":"Peanut allergy is one of the most common allergies among infants and young children, with a total Peanut allergy prevalence 8,640,527 in 2017, in the 7MM.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-02-04T10:09:36+00:00","article_modified_time":"2022-08-16T04:42:38+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/04153626\/slide2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics","name":"First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/04153626\/slide2.jpg","datePublished":"2020-02-04T10:09:36+00:00","dateModified":"2022-08-16T04:42:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Peanut allergy is one of the most common allergies among infants and young children, with a total Peanut allergy prevalence 8,640,527 in 2017, in the 7MM.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-aimmune-insmed-united-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/04153626\/slide2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/04153626\/slide2.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/04153626\/slide2-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>","<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aimmune Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Cystic Fibrosis Bronchiectasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Palforzia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peanut Allergy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peanut Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">United Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aimmune Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Non-Cystic Fibrosis Bronchiectasis<\/span>","<span class=\"advgb-post-tax-term\">Palforzia<\/span>","<span class=\"advgb-post-tax-term\">Peanut Allergy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Peanut Market<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">United Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Feb 4, 2020","modified":"Updated on Aug 16, 2022"},"absolute_dates_time":{"created":"Posted on Feb 4, 2020 3:39 pm","modified":"Updated on Aug 16, 2022 10:12 am"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7460"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7460\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7461"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7460"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7460"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}